Inaugural Cardiovascular Tech Summit

Replicating Octane’s success in Ophthalmology & Medical Aesthetics, Octane added Cardiovascular to its portfolio. Octane’s inaugural Cardiovascular Tech Summit synergized innovative solutions in cardiology with physicians, industry strategics, and investors who convened together to advance patient care.

The Summit explored strategic, process-driven innovation versus visionary inventions pathways, highlighted current buying trends of strategics and investors, reviewed current funding models of cardiology innovation, presented innovation trends, and showcased top emerging cardiology companies to our ecosystem of strategics and investors.

The founding sponsor, Dr. Arshad Quadri, inQB8 Medical Technologies, presented Edwards Lifesciences CEO, Michael Mussallem, with the Cardiovascular Innovation Prize.

Content Highlights:

• Keynote Lunch Lars Soendergaard, MD, DMSc

• Visionary Inventions: Bringing Your Ideas to Life

• Funding Innovation: Escaping the Valley of Death

• Future Insights: The Trajectory of Cardiovascular Care

• LaunchPad SBDC Company Presentations

4.6

Overall Rating

Total Attendees

Presenting at OMIF provided an amazing platform to showcase our company to serious investors, VC’s and strategic partners. I cannot overstate how outstanding the experience was from start to finish. From pre-event coaching to ‘game day’ execution the Octane team provided MACH32 with an unparalleled opportunity to reach international investors in an active health tech hub!”

Dr. Marc Curial, MD, CCFP-EM - Founder, CoCEO, MACH32

Live & Virtual Attendees

4.4

Overall Rating

Octane’s Medical Innovation Forum

Octane’s Medical Innovation Forum was held October 27-28 at the Irvine Marriott. The event attracted a nationwide array of entrepreneurs, startups, investors, strategics, medical innovation industry corporate leaders, as well as hospital systems, university scientists and researchers. SoCal companies presented the next wave of medical innovation throughout both days of the conference. Three out of the 25 companies that pitched raised capital since the Forum.

Octane’s Medical Innovation Forum serves as a unique bridge between innovation, commercialization, and connections. The focus was Entrepreneurial Intelligence (EI) –the mindset required, and critical resources, processes, and strategies needed for successful business development from ideation through to successful exits. The two-day conference discussed Entrepreneurial Intelligence in key areas such as: how to raise capital, innovation at all stages of business, management of your human capital, driving ROI with diversity, and optimizing your scientific advisory board. Our keynote was Quita Beeler Highsmith, MBA, Vice President and Chief Diversity Officer at Genentech who leads the industry in developing cutting edge medical treatments.

Octane presented Dr. Amrita Krishan with our inaugural Medical Innovation Prize. Dr. Krishnan directs the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope, seeking to make gains in one of the most rapidly changing areas in cancer research.

Octane co-founded two venture funds to fill the capital shortfall.

Creating Value with Better Insight

Venture capital fund with a unique information advantage approach and strategy to connect capital and insight with the most promising startups.

Visionary Ventures is a top decile fund focused in ophthalmology and aesthetics. Visionary Ventures believes that better information leads to better investments with exceptional returns. They gain that information through partnerships with KOL’s, industry experts, and strategic acquirers. By building a team of specialists, professionals, and industry leaders at the forefront of the process, they are tapping into a unique advantage to our venture investments.

One of their key focus areas aside from achieving exceptional returns is investing in companies that address unmet or underserved markets.

Visionary Ventures is looking for visionary and proven entrepreneurs who are turning exciting ideas into market-leading businesses. They are a focused venture capital fund from series A to commercialization. Their target investments range from $5M to $15M.